Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab

Overview

Journal Acta Derm Venereol

Specialty Dermatology

Date 2024 Oct 10

PMID 39387672

Authors

Giulia Pascolini

Feliciana Mariotti

Anna Pira

Biagio Didona

Giovanni Di Zenzo

Affiliations

Soon will be listed here.

References

Wu P, Dai Y, Li C, Chen C, Chang Y, Ma S . Dupilumab in the treatment of genodermatosis: A systematic review. J Dtsch Dermatol Ges. 2023; 21(1):7-17. DOI: 10.1111/ddg.14924. View

Mi Z, Sun F, Wang Z, Zhao Q, Pan F, Yan X . Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome. Australas J Dermatol. 2022; 63(4):527-529. DOI: 10.1111/ajd.13913. View

Bolling M, Mekkes J, Goldschmidt W, van Noesel C, Jonkman M, Pas H . Acquired palmoplantar keratoderma and immunobullous disease associated with antibodies to desmocollin 3. Br J Dermatol. 2007; 157(1):168-73. DOI: 10.1111/j.1365-2133.2007.07920.x. View

Yan S, Wu X, Jiang J, Yu S, Fang X, Yang H . Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation. Front Immunol. 2022; 13:1054422. PMC: 9773867. DOI: 10.3389/fimmu.2022.1054422. View

Cao P, Xu W, Zhang L . Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022; 13:928621. PMC: 9235912. DOI: 10.3389/fimmu.2022.928621. View

Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y . Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. Int Immunopharmacol. 2023; 125(Pt A):111157. DOI: 10.1016/j.intimp.2023.111157. View

Hamada T, Tsuruta D, Fukuda S, Ishii N, Teye K, Numata S . How do keratinizing disorders and blistering disorders overlap?. Exp Dermatol. 2012; 22(2):83-7. DOI: 10.1111/exd.12021. View

Borradori L, van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R . Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022; 36(10):1689-1704. DOI: 10.1111/jdv.18220. View

Fania L, Didona D, Pacifico V, Mariotti F, De Luca N, Abeni D . Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases. J Dermatol. 2018; 45(9):1135-1140. DOI: 10.1111/1346-8138.14529. View

10.

Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B . Evaluation of Dupilumab in Patients With Bullous Pemphigoid. JAMA Dermatol. 2023; 159(9):953-960. PMC: 10398542. DOI: 10.1001/jamadermatol.2023.2428. View

11.

Odorici G, Schenetti C, Marzola E, Monti A, Borghi A, Corazza M . Treatment of Netherton syndrome with dupilumab. J Dtsch Dermatol Ges. 2022; 20(12):1636-1640. DOI: 10.1111/ddg.14914. View

12.

Kneisel A, Hertl M . Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges. 2011; 9(10):844-56. DOI: 10.1111/j.1610-0387.2011.07793.x. View

13.

Galdo G, Fania L . A Netherton syndrome case report: Response to dupilumab treatment. Dermatol Ther. 2022; 35(11):e15862. DOI: 10.1111/dth.15862. View

14.

Razack E, Premalatha S, Rao N, Zahra A . Acanthosis palmaris in a patient with bullous pemphigoid. J Am Acad Dermatol. 1987; 16(1 Pt 2):217-9. DOI: 10.1016/s0190-9622(87)80066-x. View

15.

Miller A, Temiz L, Adjei S, Duran M, Sassmannshausen J, Dominguez A . Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients. J Drugs Dermatol. 2024; 23(6):e144-e148. DOI: 10.36849/JDD.8258. View